Companies which are more than 50% undervalued based on analyst price target.

Analysts Target

Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield	Industry
SMG	CHF 26.40	12.3%	n/a	CHF 2.6b	CHF 39.60	38.3	23.4%	3.1%	Media
TXGN	CHF 131.00	4.1%	-41.0%	CHF 1.3b	CHF 200.50	156.5	37.9%	3.1%	Media
COPN	CHF 70.50	7.0%	13.7%	CHF 1.1b	CHF 128.38	11.9	42.0%	2.7%	Pharmaceuticals & Biotech
INRN	CHF 1,358.00	4.9%	-33.3%	CHF 1.1b	CHF 2,257.14	20.3	10.9%	2.4%	Capital Goods
NEAG	CHF 31.50	1.9%	5.7%	CHF 1.0b	CHF 60.00	6.1	-26.3%	2.8%	Utilities
KURN	CHF 19.12	4.6%	-32.0%	CHF 754.5m	CHF 35.40	381.2	61.9%	n/a	Pharmaceuticals & Biotech
BSLN	CHF 54.30	4.6%	16.0%	CHF 673.1m	CHF 89.90	16.7	7.8%	n/a	Pharmaceuticals & Biotech
VETN	CHF 18.86	4.8%	-40.5%	CHF 373.9m	CHF 28.50	98.4	85.4%	2.7%	Materials
CPHN	CHF 57.40	3.2%	-22.4%	CHF 344.1m	CHF 89.73	14.7	11.7%	3.5%	Materials
MEDX	CHF 8.17	3.4%	-35.7%	CHF 332.3m	CHF 15.80	51.9	37.9%	1.2%	Healthcare
MIKN	CHF 16.65	1.2%	-0.9%	CHF 277.8m	CHF 29.80	8.5	-9.6%	3.6%	Capital Goods
NWRN	CHF 12.20	-3.5%	74.5%	CHF 253.8m	CHF 47.19	14.4	50.2%	n/a	Pharmaceuticals & Biotech
PEAN	CHF 4.30	0.7%	-33.2%	CHF 238.9m	CHF 7.87	1.8	104.4%	0%	Real Estate Management and Development
SANN	CHF 14.80	-6.4%	22.9%	CHF 221.7m	CHF 27.50	2.9	18.6%	n/a	Pharmaceuticals & Biotech
BIOV	CHF 27.00	3.8%	-24.8%	CHF 158.1m	CHF 58.26	49.8	-14.3%	n/a	Pharmaceuticals & Biotech
VARN	CHF 14.10	0.7%	-30.9%	CHF 142.8m	CHF 25.18	1.6	7.0%	0%	Real Estate Management and Development
MOLN	CHF 3.18	0%	7.3%	CHF 119.3m	CHF 9.00	1.7	16.9%	n/a	Pharmaceuticals & Biotech
XLS	CHF 18.15	-10.1%	-9.0%	CHF 103.5m	CHF 50.00	375.9	2.6%	n/a	Pharmaceuticals & Biotech
MMTX	CHF 0.21	-3.5%	n/a	CHF 31.9m	CHF 2.73	49.7	87.7%	n/a	Pharmaceuticals & Biotech
ASWN	CHF 0.61	1.7%	-43.6%	CHF 8.9m	CHF 2.00	0.5	74.2%	n/a	Media

Top Stock Picks from Analysts